Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CFB | P00751 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034423 | 0.94 | POLB (0.42) | POLBL3MBTL1SPHK1SPHK2 | |
| SCHEMBL1414126 | 0.94 | POLB (0.42) | POLBL3MBTL1SPHK1SPHK2 | |
| SCHEMBL19989685 | 0.94 | POLB (0.42) | POLBL3MBTL1SPHK1SPHK2 | |
| SCHEMBL3893332 | 0.81 | CFB (0.38) | POLBL3MBTL1ALDH1A1CFBTERT | |
| SCHEMBL2264460 | 0.77 | POLB (0.43) | POLBL3MBTL1ALDH1A1CFBTERT | |
| SCHEMBL10867079 | 0.77 | SPHK2 (0.45) | POLBL3MBTL1ALDH1A1CFBTERT | |
| SCHEMBL3460783 | 0.77 | POLB (0.43) | POLBL3MBTL1ALDH1A1CFBTERT | |
| SCHEMBL23415455 | 0.76 | SPHK2 (0.42) | POLBL3MBTL1TERTSPHK1SPHK2 | |
| SCHEMBL23415456 | 0.76 | SPHK2 (0.42) | POLBL3MBTL1TERTSPHK1SPHK2 | |
| SCHEMBL14940685 | 0.74 | POLB (0.47) | POLBL3MBTL1ALDH1A1SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1182123-C | Substituted bicyclic derivatives useful as anticancer agents | �Ʒ� | 2004-12-29 | — | — | CN | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | POLB 2389/4885L3MBTL1 990/4885ALDH1A1 393/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | POLB 2389/4885L3MBTL1 990/4885ALDH1A1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.